These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18951578)

  • 1. Re: Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features: R. J. Cohen, B. A. Shannon, M. Phillips, R. E. Moorin, T. M. Wheeler and K. L. Garrett J Urol 2008; 179: 1762-1767.
    Mai KT; Veinot JP
    J Urol; 2008 Dec; 180(6):2714; author reply 214-5. PubMed ID: 18951578
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Best practice statement on cryosurgery for the treatment of localized prostate cancer R. J. Babaian, B. Donnelly, D. Bahn, J. G. Baust, M. Dineen, D. Ellis, A. Katz, L. Pisters, D. Rukstalis, K. Shinohara and J. B. Thrasher J Urol 2008; 180: 1993-2004.
    Gans W
    J Urol; 2009 May; 181(5):2388. PubMed ID: 19303086
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. S. T. dos Reis, J. Pontes, Jr., F. E. Villanova, P. M. D. Borra, A. A. Antunes, M. F. Dall'oglio, M. Srougi and K. R. M. Leite. J Urol 2009; 181: 2320-2325.
    Ahirwar DK; Mittal RD
    J Urol; 2010 Mar; 183(3):1258. PubMed ID: 20097381
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. K. Eichler, S. Hempel, J. Wilby, L. Myers, L. M. Bachmann and J. Kleijnen, J Urol, 175: 1605-1612, 2006.
    Eskicorapci SY; Tuncay L
    J Urol; 2006 Dec; 176(6 Pt 1):2745; author reply 2745-6. PubMed ID: 17085209
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: A multi-institutional evaluation of active surveillance for low risk prostate cancer. S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R. Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau J Urol 2009; 181: 1635-1641.
    Ayres BE; Bott SR; Barber NJ; Langley SE; Montgomery BS
    J Urol; 2010 Sep; 184(3):1223-4; author reply 1224. PubMed ID: 20655069
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillonneau J Urol 2007; 178: 120-124.
    Joseph JV; Greene T
    J Urol; 2008 Feb; 179(2):789-90. PubMed ID: 18082824
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies: R. Abouassaly, N. Tan, A. Moussa and J. S. Jones J Urol 2008; 180: 911-914.
    Feldstein MS; Hentz JG
    J Urol; 2009 Apr; 181(4):1960-1; author reply 1961. PubMed ID: 19251278
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Validation of the Partin nomogram for prostate cancer in a national sample: J. B. Yu, D. V. Makarov, R. Sharma, R. E. Peschel, A. W. Partin and C. P. Gross J Urol 2010; 183: 105-111.
    Ozcan MF; Akbulut Z; Canda AE; Kilic M; Duran E; Balbay MD
    J Urol; 2010 Oct; 184(4):1571-2; author reply 1572-3. PubMed ID: 20732697
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Franclim R. Ribeiro, Rui Henrique, Ana T. Martins, Carmen Jerónimo and Manuel R. Teixeira. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 2007;52:116-25.
    Cianciulli A; Merola R; Leonardo C
    Eur Urol; 2007 Nov; 52(5):1538-9; author reply 1539-40. PubMed ID: 17764827
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial I. M. Thompson, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, E. Messing, J. Forman, J. Chin, G. Swanson, E. Canby-Hagino and E. D. Crawford J Urol 2009; 181: 956-962.
    Cheng T; Heng DY; Stewart D
    J Urol; 2009 Nov; 182(5):2531-2; discussion 2532-4. PubMed ID: 19766252
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? J. Feliciano, E. Teper, M. Ferrandino, R. J. Macchia, W. Blank, I. Grunberger and I. Colon J Urol 2008; 179: 952-955.
    Ng CF; Chan SY
    J Urol; 2008 Oct; 180(4):1570-1; author reply 1571. PubMed ID: 18718610
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: the value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses: B. A. Shannon, R. J. Cohen, H. de Bruto and R. J. Davies J Urol 2008; 180: 1257-1261.
    Park BK; Kim CK
    J Urol; 2009 Apr; 181(4):1959-60; author reply 1960. PubMed ID: 19246051
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 17. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
    Zhao J; Epstein JI
    Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. S. Jones, A. Patel, L. Schoenfield, J. C. Rabets, C. D. Zippe and C. Magi-Galluzzi. J Urol, 175: 485-488, 2006.
    Inman BA; Myers RP
    J Urol; 2006 Sep; 176(3):1252-3; author reply 1253. PubMed ID: 16890738
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Prostate cancer severity among low income, uninsured men. D. C. Miller, M. S. Litwin, J. Bergman, S. Stepanian, S. E. Connor, L. Kwan and W. J. Aronson. J Urol 2009; 181: 579-584.
    Watson RA
    J Urol; 2010 Mar; 183(3):1259-60; author reply 1260. PubMed ID: 20097378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.